BioVie Inc. (NASDAQ:BIVIW – Get Free Report) saw a significant growth in short interest in October. As of October 30th, there was short interest totaling 50,400 shares, a growth of 67.7% from the October 15th total of 30,050 shares. Based on an average trading volume of 22,475 shares, the short-interest ratio is presently 2.2 days.
BioVie Trading Down 0.4%
Shares of BioVie stock traded down $0.00 on Tuesday, hitting $0.25. 12,149 shares of the company traded hands, compared to its average volume of 52,342. The business has a 50-day simple moving average of $0.30 and a 200 day simple moving average of $0.32. BioVie has a 52 week low of $0.13 and a 52 week high of $0.79.
BioVie Inc. is a clinical-stage biopharmaceutical company developing treatments for liver and neurological disorders. Its research includes therapies for conditions associated with inflammation and impaired organ function. The company’s development programs include BIV201, an investigational continuous-infusion formulation of terlipressin being studied for ascites associated with cirrhosis, and NE3107, an investigational oral drug candidate being studied for neurodegenerative diseases, including Alzheimer’s and Parkinson’s disease.
See Also
- Five stocks we like better than BioVie
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for BioVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioVie and related companies with MarketBeat.com's FREE daily email newsletter.
